Middle Molecule Find

Rulebook › V-tags › V125

V125 Hepatitis B seroconversion: review and investigate

Written V0125 on the CMS-2567 and in QCOR.

Enforces CDC RR-05, adopted by reference at 42 CFR 494.30(a)(1)(i) · Appendix H Rev. 246, page 22 · checked 12 Nov 2026

Cited on this tag? What happens after a citation · One-page sheet for the binder

The regulation

CDC RR-05 Requirements as Adopted by Reference 42 CFR 494.30 (a)(1)(i)

Routine Testing for Hepatitis B: seroconversion

When a seroconversion occurs, review all patients’ routine laboratory test results to identify additional cases. Investigate potential sources for infection to determine if transmission might have occurred within the dialysis unit, including review of newly infected patients’ recent medical history (e.g., blood transfusion, hospitalization), history of high-risk behavior (e.g., injecting-drug use, sexual activity), and unit practices and procedures.

CMS's interpretive guidance

Interpretive Guidance § 494.30(a)(1)(i)

According to the CDC, in patients newly infected with HBV, HBsAg often is the only serologic marker initially detected. HBsAg-positive seroconversions must be reported to the State or local health department as required by law or regulation. Patients with a positive HBsAg must be isolated. Patients newly identified with HBsAg-positive status should be evaluated for the need for counseling, medical evaluation, and vaccination of contacts. Repeat HBsAg testing should be conducted, and patient should be tested for anti-HBc (including IgM anti-HBc) 1–2 months later. Six months later, the facility should repeat HBsAg testing and test for anti-HBs to determine clinical outcome and need for counseling, medical evaluation, and referral of contacts for vaccination. Patients who become HBsAg negative are no longer infectious and can be removed from isolation.

If there have been any seroconversions since last survey, there should be documentation of actions taken in response. Recognize that seroconversions should be relatively rare, and each seroconversion should be carefully analyzed for any potential that transmission occurred within the dialysis unit.

Verbatim from Appendix H Rev. 246, with CMS's headings, lists and bold. Check page 22 (the full 469-page PDF) before quoting it.

Rulebook subjects that cite it